eligibility_summary
Eligibility: Adults 18–75, B‑NHL, ≥2 prior systemic therapies, progressed/intolerant to last line, measurable disease, ECOG 0–1, >12‑wk survival, consent+15‑yr LTFU, neg preg test + 1‑yr contraception. Exclude: pregnant/lactating, HIV/active HBV/HCV, active infection/TB, >G1 AEs unresolved, recent tx (<14 d), steroids >15 mg/d (<7 d), vaccines (<4 wks), severe allergy/tocilizumab, recent heart disease, O2 sat <92%, second cancer <2 yrs, major surgery recent/planned, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: CT1190B CAR‑T cells—autologous, genetically modified T lymphocytes (adoptive cell immunotherapy). Mechanism: T cells are engineered to express a chimeric antigen receptor that binds a B‑cell surface antigen (specific antigen not stated in the record). Antigen engagement triggers CAR intracellular signaling (CD3ζ with costimulatory domains), leading to T‑cell activation, proliferation, cytokine release, and targeted cytotoxic killing of malignant B cells, study also characterizes cellular PK/PD and metabolism (expansion/persistence). Targets: Relapsed/refractory B‑cell non‑Hodgkin lymphoma cells expressing the CAR’s target antigen, pathways engaged include CAR-mediated T‑cell activation and effector cytotoxic/apoptotic pathways in tumor cells. Single‑arm, phase 1 dose‑exploration in China assessing safety and preliminary efficacy.